Signalling to Drug Resistance in CLL
Document Type
Review
Publication Date
3-1-2010
Description
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signalling pathway is constitutively active in a variety of cancers, including chronic lymphocytic leukaemia (CLL). The importance of this signalling pathway identifies it as a prime therapeutic target; however, the complexity and potential side effects of inhibiting NF-κB have thus far made the clinical use of NF-κB inhibitors a relatively unexplored resource in this disease. This article discusses the role of NF-κB in CLL as a common crossroad for pathways promoting drug resistance in CLL. We provide the background on how this pathway contributes to both spontaneous and drug-induced apoptosis. Potential new avenues to regulate this pathway in CLL are also discussed.
Citation Information
Hertlein, Erin; and Byrd, John C.. 2010. Signalling to Drug Resistance in CLL. Best Practice and Research: Clinical Haematology. Vol.23(1). 121-131. https://doi.org/10.1016/j.beha.2010.01.007 PMID: 20620976 ISSN: 1521-6926